CALCIMIMETIC ADHERENCE AND PREFERENCE IN THE MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN EUROPE: A PILOT STUDY

被引：0

作者：

Louie, Karly ^{[1
]}

Nduka, Chidozie ^{[1
]}

Taylor, Jo ^{[2
]}

Hall, Matthew ^{[3
]}

Aucella, Filippo ^{[4
]}

Artero, Josep ^{[5
]}

Na, Pablo Ure ^{[6
]}

Labriola, Laura ^{[7
]}

Andersson, Per-Olof ^{[8
]}

Evenepoel, Pieter ^{[9
]}

Oliva, Juan Carlos Gonzalez ^{[10
]}

Pisoni, Ronald ^{[11
]}

Fouqueray, Bruno ^{[12
]}

Horne, Robert ^{[13
]}

机构：

[1] AMGEN Ltd, Ctr Observat Res, Uxbridge, Middx, England

[2] Dorset Cty Hosp, Dorchester, England

[3] Nottingham Univ Hosp, Nottingham, England

[4] Fdn IRCCS Casa Sollievo Sofferenza, Nephrol & Dialysis Unit, San Giovanni Rotondo, Italy

[5] Hosp Univ Girona, Serv Nefrol, Girona, Spain

[6] Necker Enfant Malad Hosp, Serv Nephrol Dialyse, Paris, France

[7] Catholic Univ Louvain, Clin Univ St Luc, Dept Nephrol, Brussels, Belgium

[8] Vrinnevisjukhuset, Med Kliniken, Norrkoping, Sweden

[9] Univ Hosp Leuven, Div Nephrol, Leuven, Belgium

[10] Fdn Privada Hosp Mollet, Barcelona, Spain

[11] Arbor Res Collaborat Hlth, Ann Arbor, MI USA

[12] Amgen GmbH, Rotkreuz, Switzerland

[13] UCL, Sch Pharm, London, England

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2021年 / 36卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

MO524

引用

页数：2

共 50 条

[1] Calcimimetics Adherence and Preference in the Management of Uremic Secondary Hyperparathyroidism (SHPT) in Europe
Nduka, Chidozie U.
Louie, Karly S.
Taylor, Jo
Hall, Matt
Aucella, Filippo
Torres, Pablo A. Urena
Labriola, Laura
Evenepoel, Pieter
Ma, Junjie
Saleem, Najma
Pisoni, Ronald L.
Fouqueray, Bruno L.
Horne, Robert
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 694 - 694
[2] Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism
Franceschini, N
Joy, MS
Kshirsagar, A
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (08) : 1413 - 1421
[3] Calcimimetic agents for the treatment of secondary hyperparathyroidism
Goodman, WG
SEMINARS IN NEPHROLOGY, 2004, 24 (05) : 460 - 463
[4] Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention
Goodman, WG
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (02) : 204 - 207
[5] Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study
Mpio, Ignace
Boumendjel, Nourredine
Karaaslan, Husseyin
Arkouche, Walid
Lenz, Alexandra
Cardozo, Carlos
Cardozo, Jorge
Pastural-Thaunat, Myriam
Fouque, Denis
Silou, Jacques
Attaf, David
Laville, Maurice
NEPHROLOGIE & THERAPEUTIQUE, 2011, 7 (04): : 229 - 236
[6] Cinacalcet - The first calcimimetic approved for secondary hyperparathyroidism
Dang, DK
FORMULARY, 2004, 39 (10) : 482 - +
[7] A Real-World Observational Study of Calcimimetic Use in Hemodialysis (HD) Patients with Secondary Hyperparathyroidism (SHPT) in Europe
Nduka, Chidozie U.
Pernat, Andreja Marn
Camerini, Corrado
Cejka, Daniel
Ladanyi, Erzsebet
Piccoli, Giorgina B.
Boots, Johannes M.
Torregrosa, Jose-Vicente
Labriola, Laura
Rix, Marianne
Hall, Matthew
Kohnle, Matthias
Tsirtsonis, Kate
Fouqueray, Bruno L.
Floege, Juergen
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 209 - 209
[8] Secondary hyperparathyroidism disease stabilization following calcimimetic therapy
Frazao, Joao
Rodriguez, Mariano
CLINICAL KIDNEY JOURNAL, 2008, 1 : I12 - I17
[9] Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism
Dong, BJ
CLINICAL THERAPEUTICS, 2005, 27 (11) : 1725 - 1751
[10] Pharmacokinetics (PK) of calcimimetic AMG 073 in secondary hyperparathyroidism (SHPT).
Wang, B
Osborn, K
Blaisdell, P
Brenner, R
Turner, S
Laycock, J
Mooney, J
Ghobarah, H
Arends, R
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P91 - P91

← 1 2 3 4 5 →